NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Spyre Therapeutics, Inc. (SYRE) Stock Analysis

Spyre Therapeutics, Inc. (SYRE) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

SYRE

$92.95

+$1.55 (+1.70%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare SYRE with… →

SYRE Key Statistics

As of Oct 21, 2026
Trading
Open
$92.78
Previous Close
$91.40
Day's Range
92.32–95.17
52-Week Range
21.15–110.18
Volume
1.15M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
3.11
Valuation
Market Cap
$8.69B
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−1.92
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$155.20M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
93.45M
1-Year Return
+299.78%
Dividend and dates
Earnings Date
November 3, 2026
Avg Volume
1.22M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, SYRE closed at $92.95, +299.78% over 1 year.

Spyre Therapeutics, Inc. (SYRE) has a market capitalization of $8.69B.

In fiscal 2025, SYRE reported revenue of $0.00.

SYRE Stock Return by Calendar Year

Spyre Therapeutics, Inc. (SYRE) 10-year return: what $10,000 became

1 year
$10,000 $39,978
+299.78%
5 years
$10,000 $5,100
−49.00%
10 years
$10,000 $5,930
−40.70%

If you had invested $10,000 in Spyre Therapeutics, Inc. (SYRE) 10 years ago, at the close on October 21, 2016, it would have been worth $5,930 at the close on October 21, 2026: −40.70% in total, −5.09% a year. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+183.73%
2025+40.72%
2024+8.18%
2023+91.29%
2022−90.53%
2021−39.64%
2020+3.01%
2019+2.00%
2018+38.45%
2017+24.37%
2016 (partial year)−5.43%

As of October 21, 2026.

SYRE Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$155.20M—
2024$0.00−$208.02M—
2023$886.00K−$338.79M−38,238.1%
2022$2.33M−$83.82M−3,598.8%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$219.56M−$155.20M—
2024$0.00—−$208.57M−$208.02M—
2023$886.00K—−$128.56M−$338.79M−38,238.1%
2022$2.33M—−$84.78M−$83.82M−3,598.8%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

Recent News

All 20 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Spyre Therapeutics, Inc. (SYRE) is capitalised at $8.69B on the latest close. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 125.

Over the past 52 weeks the price has ranged from $21.15 to $110.18. The most recent close on file for SYRE is $92.95, dated October 21, 2026. That is +$1.55 (+1.70%) against the previous close. The latest close sits 339.58% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $0.00. The same year closed with a net loss of $155.20M. Trailing earnings per share are −1.92.

Across the 4 fiscal years on file, revenue moves from $2.33M in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative.

The reported beta is 3.11. Daily returns over the trailing 10 years annualize to a volatility of 136.36%. Over the trailing twelve months the total return is +299.78%. Across 10 years the annualized return works out at −5.09%.

Growth & Income

The record shows no dividend for SYRE.

2026 is still running; the total return is +183.73% year to date. Across the complete calendar years on file, 2023 returned +91.29% and 2022 returned −90.53%. Of the 9 complete calendar years on file, 7 finished higher.

Peer Comparison

Spyre Therapeutics, Inc. (SYRE) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Spyre Therapeutics, Inc. SYRE $8.69B —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Spyre Therapeutics, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Spyre Therapeutics, Inc.

Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD) and rheumatic diseases. The company develops SPY001, a humanized monoclonal immunoglobulin G1 antibody that is in phase-2 clinical stage designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease); and SPY002 and SPY072 – anti-TL1A mAbs designed to bind to tumor necrosis factor-like ligand 1A (TL1A). It is also developing SPY003, a clinical-stage program, which is in phase-2 clinical stage designed to bind to interleukin 23 (IL-23); SPY120, a combination of anti-a4ß7 and anti-TL1A mAbs; SPY130, a combination anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. The company was incorporated in 2013 and is based in Waltham, Massachusetts.

Visit website →